Physician profile
Wendy E Taylor
NPI 1538752407
$15,343.45
in general payments reported to CMS, 2019-2025
36 companies · $3,756 in 2025
The $3,756 reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $399 · 2022: $3,936 · 2023: $3,582 · 2024: $3,671 · 2025: $3,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Travel and Lodging: $511 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,488.55 |
| Travel and Lodging | $510.70 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,856.34 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $1,760.12 | 2022-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $1,503.00 | 2021-2025 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $1,468.44 | 2021-2025 | Rytary, Crexont, Lyvispah |
| Mdd US Operations, LLC | $1,376.04 | 2021-2025 | Gocovri, Apokyn, Xadago |
| Abbott Laboratories | $1,315.34 | 2022-2025 | Infinity |
| Boston Scientific Corporation | $641.13 | 2022-2025 | General - Dbs, Vercise |
| Alexion Pharmaceuticals, INC. | $519.97 | 2022-2025 | Ultomiris |
| Genentech USA, INC. | $451.67 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Novartis Pharmaceuticals Corporation | $405.06 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $366.72 | 2023-2025 | Rexulti, Nuedexta |
| Biogen, INC. | $357.39 | 2022-2025 | Vumerity, Leqembi, Tysabri |
| Pfizer INC. | $248.22 | 2023-2024 | |
| Eisai INC. | $219.38 | 2023-2025 | |
| Lilly USA, LLC | $207.28 | 2024-2025 | Kisunla, Amyvid, Emgality |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $200.46 | 2021-2024 | Austedo Xr, Austedo |
| Medtronic, INC. | $166.15 | 2021-2025 | Percept PC Brainsense |
| Lundbeck LLC | $161.47 | 2023-2024 | Vyepti, Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $149.96 | 2022 | |
| Tg Therapeutics, INC. | $124.84 | 2024 | |
| Kyowa Kirin, INC. | $120.86 | 2021-2023 | Nourianz |
| Mallinckrodt Hospital Products INC. | $96.03 | 2024-2025 | Acthar |
| Genzyme Corporation | $87.54 | 2025 | |
| Argenx US, INC. | $82.20 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $80.68 | 2022-2025 | Uplizna |
| Ucb, INC. | $63.85 | 2023-2025 | Zilbrysq |
| Merz Pharmaceuticals, LLC | $59.66 | 2025 | Xeomin, Ampyra, Inbrija |
| Cycle Pharmaceuticals INC | $54.55 | 2025 | Tascenso Odt |
| Horizon Therapeutics Plc | $44.42 | 2023 | Uplizna |
| Csl Behring | $32.80 | 2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $26.09 | 2025 | Hyqvia |
| Acorda Therapeutics, INC | $22.02 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.64 | 2022 | |
| Impel Pharmaceuticals INC. | $19.20 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.92 | 2025 | Wainua |
| Insightec,INC | $17.01 | 2024 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.